References
Prognostic index for Hodgkin's disease according to Hasenclever. European Society of Medical Oncology. http://www.esmo.org/education/practice-tools/web-based-practice-tools/hasenclever-index-for-hodgkins-disease.html. Accessed September 13, 2009.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339:1506–14.
Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22–8.
Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.
Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol. 2007;25:3746–52.
Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma. 2007;48:1548–55.
Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–95.
HD16 for early stage Hodgkin lymphoma. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00736320. Accessed September 13, 2009.
Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(Suppl 1):21S–30S.
Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00795613. Accessed September 13, 2009.
Tailoring treatment for B cell non-Hodgkin's lymphoma based on PET scan results mid treatment. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00324467. Accessed September 13, 2009.
Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas (PETAL). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00554164. Accessed September 13, 2009.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Basu, S. Early FDG-PET response–adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?. Eur J Nucl Med Mol Imaging 36, 2089–2090 (2009). https://doi.org/10.1007/s00259-009-1296-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-009-1296-5